logo
Stock market's haul in May comes as tariff turmoil and job angst lurk on the horizon

Stock market's haul in May comes as tariff turmoil and job angst lurk on the horizon

Yahoo2 days ago

The stock market enters June in the vicinity of record territory, right around where the year started, but with households now more wary about tariffs, the economy and their jobs.
The S&P 500 index SPX scored huge gains in May, which was its biggest monthly haul since November 2023. It closed out a whirlwind month less than 4% off its record close in February, while sailing through hazards that in more normal times could have sunk a fortune.
'You are going to panic,' Jamie Dimon tells regulators about what will happen when the bond market cracks
My daughter's boyfriend, a guest in my home, offered to powerwash part of my house — then demanded money
'The situation is extreme': I'm 65 and leaving my estate to only one grandchild. Can the others contest my will?
My ex-wife said she should have been compensated for working part time during our marriage. Do I owe her?
'He failed in his fiduciary duty': My brother liquidated our mother's 401(k) for her nursing home. He claimed the rest.
The U.S. and U.K. kicked things off with a May 8 trade agreement that included 10% tariffs on many imports of U.K. goods. The U.S. and China next met in Geneva in mid-May, where on May 12 tit-for-tat tariffs were paused. Stocks roared higher.
President Donald Trump on May 23 then lobbed a quick 50% tariff threat on goods from the European Union. Stocks came down a notch, investors responded by buying the dip, on a hunch those tariffs wouldn't emerge — and they too were quickly paused.
Stocks rounded out the month on higher ground even through a federal court ruling on May 28 invalidated most of Trumps tariffs. That ruling in less than 24 hours was paused to allow the administration's appeal to play out. Finally, the month ended with Trump blasting China on May 30, claiming aspects of the partial tariff pause were being violated, while the White House also doubling tariffs on all steel imports to 50%.
'We've had quite a decent run over the last couple of weeks,' Anthony Saglimbene, Ameriprise's chief market strategist, told MarketWatch. Stock valuations may look 'a little stretched' relative to history, but he said investors no longer appear to fear the worst-case scenario on tariffs.
What's priced into stocks is U.S. tariffs on imports will settle around 10% for much of the world, and 30% for China, he said. 'If that level is maintained — and we don't see it get worse than that — the markets have correctly rebounded, because companies can manage that environment,' he said. 'The impacts of inflation will be less draconian, and growth can remain positive.'
'But you just don't know if that's going to be the real rules of the road,' Saglimbene said.
An inflation reading for April arrived on Friday that showed the annual cost of living moved closer to prepandemic levels. But that was cold comfort to Wall Street, given the highly uncertain tariff backdrop.
'It's also old news at this point,' said Kevin Gordon, senior investment strategist at Charles Schwab & Co., on Friday. 'We know that for most of April and May, the average effective tariff rate didn't rise that much. By mid-to-late summer, that starts showing up.'
'We expect kind of a grind from here,' Gordon said of stocks.
Yet the data also reflecting a pull-forward of 'consumer spending ahead of the tariff increases,' which 'will continue to dampen household spending in the coming months, especially as they face higher prices and a softening labor market,' said Kathy Bostjancic, chief economist at Nationwide, in emailed comments.
Concerns about how companies might manage tariff costs will keep investors glued to Friday's monthly jobs report for May. Bostjancic said the sharply higher 4.9% personal savings rate in April was a cautious sign on spending, given that it was only 3.9% in November.
'Everyone is waiting to see how this settles out,' said Brent Schutte, chief investment officer, Northwestern Mutual Wealth Management Company, in a phone call. He sees something akin to a 'yo-yo' economy playing out over a few months, Schutte said, given the zig-zag on tariffs and extreme front-loading of inventory by companies and consumers hoping to avoid the worst of them.
A similar theme could also play out in stocks. 'We don't know a lot more than we knew two months ago,' Schutte said.
Read next: Americans are 'revenge saving' after years of splurging: 'Savings are a great way to have some certainty'
Tariff and economic clarity isn't expected until the Trump administration makes more concrete headway with several trade partners, hopefully over the summer.
An area to watch for signs of appetite for U.S. assets, including stocks, will be the dollar DXY, which was down 8.3% on the year as of Friday against a basket of rival currencies, according to FactSet.
'To really have the 'buy America' trade come back, you would have to see the dollar stabilize,' Gordon at Schwab said, adding that if the dollar keeps sliding and bond yields continue moving higher, it could signal a scenario of more capital flight out of the U.S.
Stocks have been suggesting any rough patches will smooth out. With first-quarter earnings nearly complete, FactSet's senior analyst John Butters pegged the S&P 500's next 12-month price-to-earnings ratio at 21.3, above the 18.4 average of the past 10 years.
Schutte at Northwestern said investors should be cautious with stocks valuations back to levels widely viewed as lofty. On the other hand, small-caps RUT could finally get a lasting boost, he said, if tariffs end up being on the lower end. It also would help if the inflation picture clears up, so the Federal Reserve can resume lowering rates.
Maulik Bhansali, a senior portfolio manager at Allspring Global Investments, said that despite fears about the appeal of U.S. assets abroad, the moment feels like a 'goldilocks' market in bonds. Any new issuance of investment-grade U.S. corporate bonds was being quickly snapped up by investors, he said.
'If you have yields in the 5-plus-precent area for most of the bond market, that's a pretty decent amount of cushion in there, to help feel you're getting well compensation for the risks out there,' he told MarketWatch.
With an eye to the jobs report, Bhansali said the biggest risk might be a report that's too positive on the labor front, one that could add to inflation worries and narrow the odds on any Fed rate cuts this year — or even put a narrow chance of a price a hike on the map.
'The reason that would be so painful is because no one is positioned for it,' Bhansali said, adding that this year has been all about bond investors expecting a steepening yield curve, where longer-duration yields BX:TMUBMUSD10Y rise more than short-end BX:TMUBMUSD02Y rates.
'That would create a lot of volatility.'
On deck, Wall Street will be hearing this week from a bunch of Federal Reserve officials, starting on Sunday, while monitoring other jobs data, manufacturing updates and the Fed's Beige Book, all before Friday's monthly employment report.
The blue-chip Dow DJIA rose 3.9% in May, its best month since January, while the S&P 500 jumped 6.2% and the Nasdaq Composite Index COMP surged 9.6%, booking their best months since Nov. 2023, according to Dow Jones Market Data.
Read: U.S.-China trade talks: Why rare-earth minerals are a sticking point in getting back on track
After the TACO trade, here comes the 'Trump Collar.' Here's what that means for stocks.
It's my dream to travel to Africa. My husband says it's not on his bucket list. Do I pay for him or go alone?
What on earth is going on with the American consumer?
My friend is getting divorced. Her husband kindly said, 'Take the house.' Is there a catch?
My husband used my money to renovate his house. Will I now get half of his property in a divorce?

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US Embassy in Kyiv warns of continued risk of Russian attacks
US Embassy in Kyiv warns of continued risk of Russian attacks

Yahoo

time35 minutes ago

  • Yahoo

US Embassy in Kyiv warns of continued risk of Russian attacks

The US Embassy in Ukraine issued a warning on 4 June about the growing risk of large-scale Russian attacks. Source: a statement on the embassy's website, as reported by European Pravda Quote: "Russia has increased the intensity of its missile and drone attacks against Ukraine in recent weeks, and there is currently a continued risk of significant air attacks. The US Embassy in Kyiv urges US citizens to exercise appropriate caution. As always, we recommend you be prepared to shelter immediately in the event an air-raid warning is issued." Details: While no specific reason is provided for the warning, it came after a special operation by the Security Service of Ukraine (SSU), codenamed Pavutyna (Spider's Web), during which dozens of Russian aircraft were hit. The last similar warning from the US Embassy was issued on the evening of 9 May, citing the risk of a large-scale air attack "over the next several days". Background: On 1 June 2025, the SSU carried out a special operation codenamed Pavutyna, one of the largest and most complex sabotage operations against Russian military aircraft. The SSU reported that the operation resulted in the destruction of 41 Russian strategic aircraft, including Tu-95, Tu-22M3 and Tu-160 strategic bombers, as well as an A-50 long-range radar detection aircraft. The North Atlantic Alliance has hailed the SSU operation targeting Russian strategic aircraft as highly successful. NATO reported that at least 40 aircraft had been damaged. Between 10 and 13 aircraft were completely destroyed. On 4 June, US President Donald Trump said he had had a "good conversation" with Russian ruler Vladimir Putin, though not one that would "lead to immediate peace". Trump added that Putin "did say, and very strongly, that he will have to respond to the recent attack on the airfields". Officially, Putin has not commented on the successful Ukrainian special operation Spider's Web. Support Ukrainska Pravda on Patreon!

NEWT GINGRICH: Pay less, know more — Trump is slashing red tape and lowering your healthcare costs
NEWT GINGRICH: Pay less, know more — Trump is slashing red tape and lowering your healthcare costs

Fox News

time37 minutes ago

  • Fox News

NEWT GINGRICH: Pay less, know more — Trump is slashing red tape and lowering your healthcare costs

One of the boldest and most consistent themes in President Donald J. Trump's healthcare agenda is his determination to reduce the role and power of middlemen. From insurance companies to pharmacy benefit managers (PBMs) – and even hospitals –these intermediaries profit from the inefficiencies of our bloated health system. The result is higher costs for American families. As I explain in my new book, "Trump's Triumph: America's Greatest Comeback," the U.S. healthcare system isn't expensive just because care is costly. It's expensive because the system is complex – by design. The third-party payment structure, whether public or private, adds layers of bureaucracy. This opens the door for middlemen to offer supposed solutions that serve their own bottom lines – not patients. It's a vicious cycle: more rules lead to more middlemen, which lead to even more rules, red tape, and rising costs. President Trump understood this – and he took action. In his first term, he issued a groundbreaking executive order on price transparency. For the first time, hospitals were required to disclose the real cost of procedures, enabling patients to compare prices before receiving care. While the Biden administration weakened enforcement, Trump doubled down in his second term with an even stronger push for what he called "radical transparency." Radical transparency is the antidote to healthcare's worst inefficiencies. When patients and employers can see wide price differences for the same procedures – even within the same hospital system – the games played behind the scenes get exposed. These inflated prices often have little to do with quality and everything to do with how well insurers negotiate – or how many middlemen take a cut. The same is true for prescription drugs. PBMs – giant corporations that control which drugs are covered and at what cost – use their market power to inflate prices. Three PBMs control 80 percent of the market. They're often subsidiaries of major insurers, forming vertically integrated monopolies. New data from the Pacific Research Institute shows that most PBMs skim more money off high-cost prescriptions than European countries charge. It's no wonder Americans are paying more. Hospitals play a role as well. Many exploit a well-intentioned federal program known as 340B, which allows them to purchase drugs at steep discounts. Instead of passing the savings to patients, they bill insurers full price and pocket the difference. The program was meant to expand care for low-income patients, but there's little oversight to ensure this happens. President Trump's recent executive order on drug pricing targets this broken system. By creating a pathway for manufacturers to sell directly to patients, health plans, pharmacies, and clinics – without the markup – he's offering a way to bypass the middlemen. This isn't theory – it's already working. When insulin makers launched direct-to-consumer programs, they sold the same drug at one-fourth the price patients were paying through insurance – while still making a profit. That's the power of real market competition – without a single government price control. This stands in sharp contrast to the Left's top-down vision. Whether it's price controls, centralized purchasing, or government-run insurance, the left's answer is always more bureaucracy. But more bureaucracy means more complexity – and more room for middlemen to thrive. Perhaps the most visionary part of President Trump's health care agenda is his call to Make America Healthy Again. For decades, we've operated a "sick care" system focused on treating illness after it strikes. Trump's approach is different. It emphasizes prevention, lifestyle, and personal responsibility – turning Americans from passive recipients into active participants in their own health. In this model, the government's role isn't to run the system but to create an environment in which patients and doctors can lead – with access to better tools, more transparency, and useful information. That means clearer labeling for ultra-processed foods, ensuring gold standard scientific data free of conflicts of interest, and addressing environmental factors that contribute to chronic disease. These kinds of structural reforms empower people to make informed choices and live healthier lives – without mandates or micromanagement. It's a model that eliminates the ultimate middleman: the system itself. President Trump's leadership has laid the groundwork for a transparent, patient-centered, free-market healthcare system. But the job isn't done. Congress should join him in continuing this fight – not just to lower costs, but to restore power to the American people. America deserves a healthcare system that benefits Americans – not industry middlemen.

Why CoreWeave Rocketed 170% in May
Why CoreWeave Rocketed 170% in May

Yahoo

time44 minutes ago

  • Yahoo

Why CoreWeave Rocketed 170% in May

CoreWeave rallied in May off of the April "liberation day" bottom. The company held its first earnings release, beating expectations and raising guidance. Nvidia disclosed that it raised its investment in the company. 10 stocks we like better than CoreWeave › Shares of CoreWeave (NASDAQ: CRWV) rocketed 169.5% in May, according to data from S&P Global Market Intelligence. CoreWeave had a busy month, not only recovering from April's "Liberation Day" along with the rest of the sector, but also holding its first earnings report since its March 28 initial public offering (IPO). Additionally, key customer and supplier Nvidia (NASDAQ: NVDA) disclosed that it had increased its investment in the company. Virtually all technology stocks and artificial intelligence (AI) stocks recovered in a big way after May 12, when the U.S. and China ratcheted down their mutual tariffs for 90 days in order to let trade talks proceed. The sky-high China tariffs had been at the heart of the worries over President Trump's tariff war, which had especially weighed on the semiconductor and AI sectors. Shortly after the rollback of China tariffs, CoreWeave also held its first-ever earnings release. In that release, CoreWeave beat revenue expectations handily. And while earnings per share missed by a lot, that was caused by one-time stock compensation costs associated with the IPO. Moreover, CoreWeave raised its revenue guidance for the year well above analyst estimates, although it also increased its outlook for capital expenditures. While investors had something of a mixed reaction to earnings, most Wall Street analysts raised their price targets afterward. But just days later, CoreWeave saw a massive spike in its stock after it was revealed that AI chip darling Nvidia had increased its investment in the company. That was followed by even larger analyst price target increases the following week. Not only did CoreWeave have a monster month of May, but the stock has also surged to begin June, following news of a 15-year, $7 billion data center expansion agreement with data center operator Applied Digital (NASDAQ: APLD). Given the massive spike in the stock price, there's a degree of meme stock momentum right now in CoreWeave. So investors should be careful with the stock at this valuation, which currently sits at about 15 times this year's revenue outlook. That's a high price for a stock with high investment needs and some substantial risks. One concern is that CoreWeave has to invest substantial amounts in fixed assets ahead of receiving revenues from its contracts. However, it appears investors are encouraged by the more aggressive growth outlook and willing to look past upfront investment needs in fixed costs that will probably require CoreWeave to raise more capital. Another risk that concerns me is the company's circular relationship with Nvidia, which is both a customer and, obviously, a key supplier. While AI demand and demand for Nvidia chips appears quite strong for now, should either demand ever slow down, CoreWeave could run into problems. Before you buy stock in CoreWeave, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CoreWeave wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Billy Duberstein and/or his clients have no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool has a disclosure policy. Why CoreWeave Rocketed 170% in May was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store